The Rise of GLP-1 Agonists in Cardiovascular Care
For years, GLP-1 medications like Ozempic, Wegovy, and Trulicity have dominated headlines for their impact on weight loss. But beyond the before-and-after photos, something far more important is happening: these drugs are showing benefits for heart health.
In fact, GLP-1s may represent one of the most promising developments in cardiometabolic medicine in decades, and they’re reshaping how providers think about prevention, risk management, and long-term outcomes.
Beyond the Scale: Protecting the Heart
GLP-1 receptor agonists were originally designed to improve blood sugar control in type 2 diabetes, but clinical trials also revealed additional cardiovascular benefits:
- The LEADER trial (liraglutide): Found a 13% reduction in major adverse cardiovascular events (MACE) in high-risk patients with diabetes.
- The SUSTAIN-6 trial (semaglutide): Showed a 26% reduction in cardiovascular death, non-fatal heart attack, or stroke.
- The SELECT trial: Demonstrated semaglutide reduced cardiovascular events in patients with established cardiovascular disease but without diabetes.
- The STEP-HFpEF trial: Found improvements in symptoms and fewer hospitalizations for patients with obesity-related heart failure with preserved ejection fraction (HFpEF) — but it’s important to note that results should not be generalized to all heart failure patients.
These findings confirm what providers are seeing in practice: GLP-1s don’t just help patients lose weight, they can also protect the heart in carefully selected populations.
What This Means for Patients
For patients with obesity, diabetes, or established cardiovascular disease, GLP-1s may offer:
- Lower risk of cardiovascular events like heart attack or stroke
- Improved quality of life through weight loss, blood pressure control, and better cholesterol management
- Hope for symptom relief in obesity-related HFpEF
Still, these medications are not for everyone. GLP-1s can be costly, require careful monitoring, and work best when integrated into an overall care plan that considers long-term value, patient adherence, and safety.
GLP-1s and the Future of Value-Based Cardiology
While cardiologists are unlikely to prescribe GLP-1s to every patient, these medications are increasingly viewed as a potential component of comprehensive, value-based cardiometabolic care. For providers, this means:
- Staying informed about evolving clinical trial data and guideline updates
- Collaborating with endocrinologists and primary care physicians on appropriate prescribing
- Educating patients about realistic expectations, cost considerations, and potential side effects
- Ensuring any use fits into value-based, patient-centered care models
How CCA Sees the Future
At Cardiac Care Alliance, we view the rise of GLP-1s as part of a broader shift: cardiovascular care is becoming more preventive, more holistic, and more connected than ever before. CCA is exploring how GLP-1s may fit into comprehensive cardiometabolic care models. This ensures that if and when these therapies are incorporated, they’re used appropriately, cost-effectively, and in alignment with value-based care.
Because at the end of the day, innovation only matters if it truly reaches the patients who need it most.
Interested in learning more? Contact Us to explore how CCA supports cardiologists and health systems in advancing smarter cardiovascular care.
